Viz.ai, a provider of AI-driven disease detection and care coordination, has partnered with Avicenna.AI to integrate its advanced medical imaging tools, CINA-iPE and CINA-ASPECTS, into the Viz.ai One platform. This integration equips clinicians with enhanced insights from CT scans, improving the speed and accuracy of diagnosis and treatment. By looking at CT brain pictures, the CINA-ASPECTS tool gives an objective measure of how bad a stroke is. The CINA-iPE tool finds incidental pulmonary embolism, a potentially life-threatening disease that is often missed in regular CT chest scans. Together, these tools strengthen Viz.ai One’s ability to facilitate real-time communication and optimize care pathways for faster, better-informed clinical decisions.
Viz.ai serves over 1,700 hospitals and health systems across the U.S. and Europe, leveraging AI to accelerate care coordination and improve patient outcomes. Founded in 2018, Avicenna.AI specializes in AI solutions for detecting critical pathologies through deep learning. By combining their expertise, the two companies aim to empower healthcare professionals with reliable, AI-powered tools to enhance diagnostic accuracy and patient care efficiency. With Avicenna’s FDA-cleared technologies integrated into Viz.ai’s comprehensive platform, this collaboration underscores a shared commitment to innovation in healthcare, ultimately benefiting patients through faster, more effective treatment solutions.
